EYEN Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology...

Stats
Šios dienos apimtis	951 545
Vidutinė apimtis	1.33M
Rinkos kapitalizacija	47.77M
EPS	$0 ( 2024-03-18 )
Kita pelno data	( $-0.250 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.420
ATR14	$0.00900 (0.96%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Grant Stuart M.	Buy	100 000	Common stock, par value $0.0001
2024-03-19	Grant Stuart M.	Buy	50 000	Common stock, par value $0.0001
2024-03-08	Grant Stuart M.	Buy	10 717	Common stock, par value $0.0001
2024-02-12	Gandolfo John P	Buy	60 000	Stock Option (right to buy)
2024-02-12	Rowe Michael M	Buy	75 000	Stock Option (right to buy)

INSIDER POWER
68.98
Last 95 transactions
Buy: 2 919 948 \| Sell: 334 000

Tūris Koreliacija

Ilgas: 0.10 (neutral)

Trumpas: 0.87 (strong)

Signal:(51.454) Same movement expected

Eyenovia Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
WINA	0.968
INZY	0.966
AMTBB	0.961
CSPI	0.955
TAYD	0.95
SVFAU	0.948
SVFA	0.947
HROW	0.946
BRLI	0.944
HSKA	0.944

10 Labiausiai neigiamai susiję koreliacijos
CYRN	-0.957
TLGT	-0.936
GNTY	-0.935
FVCB	-0.934
ONEM	-0.933
RPRX	-0.93
PEAR	-0.93
VORB	-0.929
BWB	-0.929
AROW	-0.927

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Eyenovia Inc Koreliacija - Valiuta/Žaliavos

0.14
( neutral )

0.05
( neutral )

0.00
( neutral )

-0.42
( neutral )

0.00
( neutral )

-0.22
( neutral )

Eyenovia Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$3 787.00
Bruto pelnas:	$-783 208 (-20 681.49 %)
EPS:	$-0.660

FY	2023
Pajamos:	$3 787.00
Bruto pelnas:	$-783 208 (-20 681.49 %)
EPS:	$-0.660

FY	2022
Pajamos:	$0
Bruto pelnas:	$-307 430 (0.00 %)
EPS:	$-0.820

FY	2021
Pajamos:	$14.00M
Bruto pelnas:	$12.40M (88.57 %)
EPS:	$-0.607

Financial Reports:

No articles found.

Eyenovia Inc

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.